GLOPID-R

CEPI

Broadening protection against SARS-COV-2 and new broadly protective Betacoronavirus candidate vaccines

The main focus of this call for proposals is to support the research and development of novel immunogens (i.e.: antigens that elicit an adaptive immune response) for use in vaccines that can elicit durable, broadly protective immune responses.

This opportunity is open, worldwide, to research and development organisations with expertise in vaccine development.

Scope

The Call is divided into two parts with varying timelines:

  • A broadly protective vaccine against new emerging variants and variants of concern of the SARS-CoV-2 virus (BPCoV2), with funding up to 18-24 months to achieve clinical proof of concept (POC).
  • A broadly protective Betacoronavirus (BPBC) vaccine with funding potentially awarded for up to 4 years to demonstrate clinical POC.

The common scope of this Call for Proposals is the immunogen design inducing broadly protective and lasting immunogenicity against Betacoronaviruses and/or the emerging variants of SARS-CoV-2. It is recognized that a BPBC vaccine may also function as a BPCov2 vaccine.

The vaccine technology platform utilized should be suitable for rapid response application based on a proven and established technology, or a novel platform technology that meets the goals of the Call.

Read the full request for proposal

  • Call budget: US$200M
  • Call opens: April 1st, 2021
  • Application deadline: BPCoV2 call May 31st, 2021 & BPBC call – October 1st, 2021
EU Flag

The GloPID-R Secretariat is a project which receives funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 874667.